ArticleApoptosis : an international journal on programmed cell death2025
High-dose tamoxifen impairs the homeostasis of the intestinal stem cell niche by enhancing fatty acid degradation and damaging mitochondria.
Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dysfunction of mitochondria in intestinal epithelial cells: a key player in the pathogenesis of inflammatory bowel diseases.Gastroenterology report · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Tamoxifen is therapeutically employed for breast and ovarian cancers, and it is also widely utilized to activate Cre recombinase in transgenic mice containing Cre-ERT locus. However, high dose tamoxifen (HDTAM) has been reported to induce many side effects in several organs and tissues. Intestinal stem cells (ISCs) play pivotal roles in sustaining the epithelial homeostasis and intestinal functionality. In this study, we systematically investigated the influences of HDTAM on ISCs and their niche. It was found that HDTAM treatment decreased the body weight and the length of small intestines (SI), damaged the gross and histological morphology of SI. Notably, HDTAM dramatically inhibited the proliferation, differentiation, gene expression of ISCs in vivo and in vitro. RNA-Seq results demonstrated that these changes caused by HDTAM were significantly correlated with the degradation of intestinal fatty acids and the process of fatty acid oxidation. Mechanistically, HDTAM impaired the morphology and function of mitochondria of intestinal epithelial cells, increased the endoplasmic reticulum (ER) contents in Paneth cells. Therefore, we concluded that HDTAM could result in a disruption for the function and homeostasis of ISCs, and the interruption of fatty acid utilization might be responsible for these effects. This study implicates a careful use and evaluation of tamoxifen is in necessity when it's used for intestinal research.
Indexed as
Identifiers
40956549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.